Cellyan Biotechnology shares drop 20.79% after hours after Nasdaq extends $1 bid-price deadline to Jan. 11, 2027
AI Market Summary
Cellyan Biotechnology (HKPD) received a further 180-day Nasdaq extension to regain the $1 minimum bid requirement, but the stock sold off sharply after hours, reinforcing perceived delisting risk. While trading continues and other listing standards are met, the need to sustain a $1 bid (potentially via reverse split) highlights ongoing weakness and can pressure liquidity and investor confidence in the name.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.96%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Cellyan Biotechnology (NASDAQ: HKPD) has received an additional 180-day period from Nasdaq to regain compliance with the exchange’s $1.00 minimum closing bid price requirement, extending the deadline to Jan. 11, 2027. The stock is trading at $0.34 and is down 69.03% over the past 12 months, giving it a market capitalization of about $10.2 million. The notice does not halt trading, but it underscores the risk of delisting and adds pressure on the shares.
